Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30

PubMed  Google Scholar 

Micalizzi DS, Maheswaran S (2018) On the trail of invasive cells in breast cancer. Nature 554(7692):308–309

Article  CAS  PubMed  Google Scholar 

Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C, Piccart M (2014) Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol 32(25):2794–2803

Article  PubMed  Google Scholar 

Pellegrino B, Hlavata Z, Migali C, De Silva P, Aiello M, Willard-Gallo K, Musolino A, Solinas C (2021) Luminal breast cancer: risk of recurrence and tumor-associated immune suppression. Mol Diagn Ther 25(4):409–424

Article  CAS  PubMed Central  PubMed  Google Scholar 

Li ZH, Hu PH, Tu JH, Yu NS (2016) Luminal B breast cancer: patterns of recurrence and clinical outcome. Oncotarget 7(40):65024

Article  PubMed Central  PubMed  Google Scholar 

Prat A et al (2020) Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 21(1):33–43

Article  CAS  PubMed  Google Scholar 

Babyshkina N, Vtorushin S, Dronova T, Patalyak S, Slonimskaya E, Kzhyshkowska J, Cherdyntseva N, Choynzonov E (2019) Impact of estrogen receptor α on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer. Clin Exp Med 19(4):547–556

Article  PubMed  Google Scholar 

Von Minckwitz G, Procter M, De Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A (2017) Adjuvant Pertuzumab and trastuzumab in early HER2-positive breast cancer. New England J Med 377(2):122–131

Article  Google Scholar 

Hashmi AA, Aijaz S, Khan SM, Mahboob R, Irfan M, Zafar NI, Nisar M, Siddiqui M, Edhi MM, Faridi N, Khan A (2018) Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients. World J Surg Oncol 16(1):1

Article  PubMed Central  PubMed  Google Scholar 

González-Woge M et al (2024) The expression profiles of lncRNAs are associated with neoadjuvant chemotherapy resistance in locally advanced, luminal B-type breast cancer. Int J Mol Sci 25(15):8077

Article  PubMed Central  PubMed  Google Scholar 

Altundag K (2019) Definition of luminal B HER-2-negative breast cancer subtype should be revisited. J Buon 24(4):1735

PubMed  Google Scholar 

Gong G, Kwon MJ, Han J, Lee HJ, Lee SK, Lee JE, Lee SH, Park S, Choi JS, Cho SY, Ahn SH, Lee JW, Cho SR, Moon Y, Nam BH, Nam SJ, Choi YL, Shin YK (2017) A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer. Sci Rep 7:45554

Article  CAS  PubMed Central  PubMed  Google Scholar 

Rajc J, Fröhlich I, Mrčela M, Tomaš I, Flam J (2018) Prognostic impact of low estrogen and progesterone positivity in luminal B (Her2 negative) breast cancer. Acta Clin Croat 57(3):425–433

PubMed Central  PubMed  Google Scholar 

Tan S, Fu X, Xu S, Qiu P, Lv Z, Xu Y, Zhang Q (2021) Quantification of Ki67 change as a valid prognostic indicator of luminal B type breast cancer after neoadjuvant therapy. Pathol Oncol Res 20(27):1609972

Article  Google Scholar 

Esserman LJ, Berry DA, DeMichele A, Carey LA, Davis SE, Buxton MB et al (2022) Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 2 Trial. J Clin Oncol 40(9):956–967. https://doi.org/10.1200/JCO.21.01610

Article  Google Scholar 

von Minckwitz G, Huang CS, Mano MS et al (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380(7):617–628

Article  Google Scholar 

Winchester DJ, et al 2025 Member of the Ninth Edition AJCC Neoadjuvant Breast Expert Panel; TransSCOT Consortium. Novel Postneoadjuvant Prognostic Breast Cancer Staging System. J Clin Oncol. JCO2401739.

Samiei S, Simons JM, Engelen SME, Beets-Tan RGH, Classe JM, Smidt ML (2021) Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with ınitially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg 156(6):e210891

Article  PubMed Central  PubMed  Google Scholar 

Lv J, Ren J, Zheng J, Zhang F, Han M (2022) Prognosis of tumor microenvironment in luminal B-type breast cancer. Dis Markers 2022:5621441

Article  PubMed Central  PubMed  Google Scholar 

Sereda EE, Kolegova ES, Kakurina GV, Korshunov DA, Sidenko EA, Doroshenko AV, Slonimskaya EM, Kondakova IV (2022) Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes. Transl Breast Cancer Res 30(3):23

Article  Google Scholar 

Tang LC, Jin X, Yang HY, He M, Chang H, Shao ZM, Di GH (2015) Luminal B subtype: a key factor for the worse prognosis of young breast cancer patients in China. BMC Cancer 29(15):201

Article  Google Scholar 

Li Y, Yang D, Yin X, Zhang X, Huang J, Wu Y, Wang M, Yi Z, Li H, Li H, Ren G (2020) Clinicopathological characteristics and breast cancer-specific survival of patients with single hormone receptor-positive breast cancer. JAMA Netw Open 3(1):e1918160

Article  PubMed Central  PubMed  Google Scholar 

Curtis C, Shah S, Chin SF et al (2012) The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486:346–352

Article  CAS  PubMed Central  PubMed  Google Scholar 

Li ZH, Hu PH, Tu JH, Yu NS (2022) Prognostic significance of progesterone receptor status in breast cancer: a review and future directions. Drug Des Devel Ther 16:305–318

Article  CAS  PubMed Central  PubMed  Google Scholar 

Chen W, Altshuler RD, Daschner P, Salvador Morales C, St Germain DC, Guida J, Prasanna PGS, Buchsbaum JC (2024) Older adults with cancer and common comorbidities-challenges and opportunities in improving their cancer treatment outcomes. J Natl Cancer Inst 116(11):1730–1738

Article  PubMed Central  PubMed  Google Scholar 

Benderra MA, Serrano AG, Paillaud E, Tapia CM, Cudennec T, Chouaïd C, Lorisson E, de la Taille A, Laurent M, Brain E, Bringuier M, Gligorov J, Caillet P, Canoui-Poitrïne F (2023) Prognostic value of comorbidities in older patients with cancer: the ELCAPA cohort study. ESMO Open 8(5):101831

Article  PubMed Central  PubMed  Google Scholar 

Hulen E, Zullig LL, Pleasant T, Wall R, Edwards ST, Ono S (2025) Attitudes towards mammography among rural-residing women veterans overdue for breast cancer screening. Mil Med 9:usaf252

Article  Google Scholar 

Carew JW, Radulescu SC, Zhang L, Ungurean C, Calomfirescu C, Furtunescu F, Soliman AS (2025) Breast cancer mortality in Romania: trends, regional and rural-urban inequalities, and policy implications. BMC Cancer 25(1):1038

Article  PubMed Central  PubMed  Google Scholar 

Moura T, Caramelo O, Silva I, Silva S, Gonçalo M, Portilha MA, Moreira JN, Gil AM, Laranjeira P, Paiva A (2025) Early-stage luminal B-like breast cancer exhibits a more immunosuppressive tumor microenvironment than luminal a-like breast cancer. Biomolecules 15(1):78

Article  CAS  PubMed Central  PubMed  Google Scholar 

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784

Article  Google Scholar 

Anurag M, Zhu M, Huang C, Vasaikar S, Wang J, Hoog J, Burugu S, Gao D, Suman V, Zhang XH, Zhang B, Nielsen T, Ellis MJ (2020) Immune checkpoint profiles in luminal B breast cancer (Alliance). J Natl Cancer Inst 112(7):737–746

Article  PubMed  Google Scholar 

Dumitrescu RG (2018) Interplay between genetic and epigenetic changes in breast cancer subtypes. Methods Mol Biol 1856:19–34

Article  PubMed  Google Scholar 

Swarbrick A, Fernandez-Martinez A, Perou CM (2024) Gene-expression profiling to decipher breast cancer inter- and intratumor heterogeneity. Cold Spring Harb Perspect Med 14(1):a041320

Article  CAS  PubMed  Google Scholar 

Ozaki A, Matsuda A, Maemura Y, Tada Y, Kasai T, Nagashima Y, Onaga C, Hara Y, Kitabatake K, Tsukimoto M, Tamori S, Sasaki K, Ohno S, Akimoto K (2024) Luminal B breast cancer coexpressing p62 and ALDH1A3 Is less susceptible to radiotherapy.